Qualitative plasma viral load determination as a tool for screening of viral reservoir size in PWH.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 11 2022
01 11 2022
Historique:
entrez:
29
9
2022
pubmed:
30
9
2022
medline:
1
10
2022
Statut:
ppublish
Résumé
Suppression of viral replication in patients on antiretroviral therapy (ART) is determined by plasma viral load (pVL) measurement. Whenever pVL reaches values below the limit of quantification, the qualitative parameter 'target detected' or 'target not detected' is available but often not reported to the clinician. We investigated whether qualitative pVL measurements can be used to estimate the viral reservoir size. The study recruited 114 people with HIV (PWH) who are stable on ART between 2016 and 2018. The percentage of pVL measurements qualitatively reported as 'target detected' (PTD) within a 2-year period was calculated. t-DNA and US-RNA were used to estimate viral reservoir size and were quantified on peripheral blood mononuclear cells (PBMCs) using droplet digital PCR. A median of 6.5 pVL measurements over a 2-year period was evaluated for each participant to calculate PTD. A positive correlation was found between t-DNA and PTD (r = 0.24; P = 0.011) but not between US-RNA and PTD (r = 0.1; P = 0.3). A significantly lower PTD was observed in PWH with a small viral reservoir, as estimated by t-DNA less than 66 copies/106 PBMCs and US-RNA less than 10 copies/106 PBMCs, compared with PWH with a larger viral reservoir (P = 0.001). We also show that t-DNA is detectable whenever PTD is higher than 56% and that ART regimen does not affect PTD. Our study shows that PTD provides an efficient parameter to preselect participants with a small viral reservoir based on already available pVL data for future HIV cure trials.
Identifiants
pubmed: 36172869
doi: 10.1097/QAD.0000000000003352
pii: 00002030-202211010-00002
doi:
Substances chimiques
DNA, Viral
0
RNA, Viral
0
RNA
63231-63-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1761-1768Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Siliciano RF, Greene WC. HIV latency . Cold Spring Harb Perspect Med 2011; 1:a007096.
Barton K, Winckelmann A, Palmer S. HIV reservoirs during suppressive therapy . Trends Microbiol 2017; 24:345–355.
Churchill MJ, Deeks SG, Margolis DM, Siliciano RF, Swanstrom R. HIV reservoirs: what, where and how to target them . Nat Rev Microbiol 2015; 14:55–60.
Wong J, Yukl S. Tissue reservoirs of HIV . Physiol Behav 2016; 11:362–370.
Steingrover R, Pogány K, Fernandez Garcia E, Jurriaans S, Brinkman K, Schuitemaker H, et al. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy . AIDS 2008; 22:1583–1588.
De Scheerder MA, Vrancken B, Dellicour S, Schlub T, Lee E, Shao W, et al. HIV rebound is predominantly fueled by genetically identical viral expansions from diverse reservoirs . Cell Host Microbe 2019; 26:347.e7–358.e7.
Abdel-Mohsen M, Richman D, Siliciano RF, Nussenzweig MC, Howell BJ, Martinez-Picado J, et al. BEAT-HIV Delaney Collaboratory to Cure HIV-1 infection. Recommendations for measuring HIV reservoir size in cure-directed clinical trials . Nat Med 2020; 26:1339–1350.
Lambrechts L, Cole B, Rutsaert S, Trypsteen W, Vandekerckhove L. Emerging PCR-based techniques to study HIV-1 reservoir persistence . Viruses 2020; 12:1–12.
Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy . Science 1997; 278:1295–1300.
Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells . Nat Med 2003; 9:727–728.
Cillo AR, Sobolewski MD, Bosch RJ, Fyne E, Piatak M, Coffin JM, Mellors JW. Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy . Proc Natl Acad Sci U S A 2014; 111:7078–7083.
Procopio FA, Fromentin R, Kulpa DA, Brehm JH, Bebin AG, Strain MC, et al. A novel assay to measure the magnitude of the inducible viral reservoir in HIV-infected individuals . EBioMedicine 2015; 2:874–883.
Butler SL, Hansen MST, Bushman FD. A quantitative assay for HIV DNA integration in vivo . Nat Med 2001c; 7:631–634.
Liszewski M, Yu J, O’Doherty U. Detecting HIV-1 integration by repetitive-sampling Alu-gag PCR . Methods 2009; 47:254–260.
Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies . PLoS Pathog 2013; 9:e1003174.
Avettand-Fènoë V, Hocqueloux L, Ghosn J, Cheret A, Frange P, Melard A, et al. Total HIV-1 DNA, a marker of viral reservoir dynamics with clinical implications . Clin Microbiol Rev 2016; 29:859–880.
Pasternak AO, Jurriaans S, Bakker M, Prins JM, Berkhout B, Lukashov VV. Cellular levels of HIV unspliced RNA from patients on combination antiretroviral therapy with undetectable plasma viremia predict the therapy outcome . PLoS One 2009; 4:e8490.
Pasternak AO, Grijsen ML, Wit FW, Bakker M, Jurriaans S, Prins JM, et al. Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART . JCI Insight 2020; 5:1–37.
Van Gulck E, Heyndrickx L, Bracke L, Coppens S, Florence E, Buvé A, et al. Control of viral replication after cessation of HAART . AIDS Res Ther 2011; 8:6.
Lau JSY, Smith MZ, Lewin SR, McMahon JH. Clinical trials of antiretroviral treatment interruption in HIV-infected individuals . AIDS 2019; 33:773–791.
Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, et al. A novel quantitative approach for measuring the reservoir of latent HIV-1 proviruses . Nature 2019; 566:120–125.
Gaebler C, Lorenzi JCC, Oliveira TY, Nogueira L, Ramos V, Lu CL, Pai JA, et al. Combination of quadruplex qPCR and next-generation sequencing for qualitative and quantitative analysis of the HIV-1 latent reservoir . J Exp Med 2019; 216:2253–2264.
Leth S, Schleimann MH, Nissen SK, Højen JF, Olesen R, Graversen ME, et al. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial . Lancet HIV 2016; 3:e463–e472.
Pannus P, Rutsaert S, De Wit S, Allard SD, Vanham G, Cole B, et al. Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription . J Int AIDS Soc 2020; 23:e25453.
Kiselinova M, Geretti AM, Malatinkova E, Vervisch K, Beloukas A, Messiaen P, et al. HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens . J Antimicrob Chemother 2015; 70:3311–3316.
Malatinkova E, Kiselinova M, Bonczkowski P, Trypsteen W, Messiaen P, Vermeire J, et al. Accurate quantification of episomal HIV-1 two-long terminal repeat circles by use of optimized DNA isolation and droplet digital PCR . J Clin Microbiol 2015; 53:699–701.
Ceelen L, De Craene J, De Spiegelaere W. Evaluation of normalization strategies used in real-time quantitative pcr experiments in heparg cell line studies . Clin Chem 2014; 60:451–454.
Fischer M, Günthard HF, Opravil M, Joos B, Huber W, Bisset LR, et al. Residual HIV-RNA levels persist for up to 2.5 years in peripheral blood mononuclear cells of patients on potent antiretroviral therapy . AIDS Res Hum Retroviruses 2000; 16:1135–1140.
Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, et al. QUEST Study Group. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005 . Clin Infect Dis 2007; 45:381–390.
Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, Fauci AS. Relationship between residual plasma viremia and the size of HIV proviral DNA reservoirs in infected individuals receiving effective antiretroviral therapy . J Infect Dis 2011; 204:135–138.
Parisi SG, Sarmati L, Andreis S, Scaggiante R, Cruciani M, Ferretto R, et al. Strong and persistent correlation between baseline and follow-up HIV-DNA levels and residual viremia in a population of naïve patients with more than 4 years of effective antiretroviral therapy . Clin Microbiol Infect 2015; 21:288.e5–288.e7.
Yerly S, Perneger TV, Vora S, Hirschel B, Perrin L. Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection . AIDS 2000; 14:2805–2812.
Rouzioux C, Hubert JB, Burgard M, Deveau C, Goujard C, Bary M, et al. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4 + T cell counts . J Infect Dis 2005; 192:46–55.
Bachmann N, von Siebenthal C, Vongrad V, Turk T, Neumann K, Beerenwinkel N, et al. Swiss HIV Cohort Study. Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART . Nat Commun 2019; 10:3193.
Buzón MJ, Massanella M, Llibre JM, Esteve A, Dahl V, Puertas MC, et al. HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects . Nat Med 2010; 16:460–465.
Hatano H, Strain MC, Scherzer R, Bacchetti P, Wentworth D, Hoh R, et al. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV Infection: a randomized, placebo-controlled trial . J Infect Dis 2013; 208:1436–1442.
Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis . Clin Infect Dis 2005; 41:1326–1332.
Sörstedt E, Nilsson S, Blaxhult A, Gisslén M, Flamholc L, Sönnerborg A, Yilmaz A. Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels . BMC Infect Dis 2016; 16:305.
Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, et al. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy . Antivir Ther 2008; 13:927–936.
Kumar A, Abbas W, Bouchat S, Gatot JS, Pasquereau S, Kabeya K, et al. Limited HIV-1 reactivation in resting CD4 + T cells from aviremic patients under protease inhibitors . Sci Rep 2016; 6:1–7.
Pasternak AO, Vroom J, Kootstra NA, Wnm Wit F, Bruin M, De Francesco D, Bakker M, et al. Nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels as compared with therapy based on protease inhibitors . Elife 2021; 10:e68174.
Darcis G, Maes N, Pasternak AO, Sauvage AS, Frippiat F, Meuris C, et al. Detectability of HIV residual viremia despite therapy is highly associated with treatment with a protease inhibitor-based combination ART . Antimicrob Agents Chemother 2019; 64:e01902-19.